［1］吴敏,李英花.骨髓微环境介导蛋白酶体抑制剂治疗多发性骨髓瘤耐药机制研究现状［J］.现代肿瘤医学,2023,31(22):4289-4294.
WU Min,LI Yinghua.Current status of research on the mechanism of drug resistance of bonemarrow microenvironment-mediated proteasome inhibitors in thetreatment of multiple myeloma［J］.Modern Oncology,2023,31(22):4289-4294.
［2］YU B,JIANG T,LIU D.BCMA-targeted immunotherapy for multiple myeloma［J］.J Hematol Oncol,2020,13(1):125.
［3］TAI YT,ACHARYA C,AN G,et al.APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment［J］.Blood,2016,127(25):3225-3326.
［4］CASSINELLI G,RONCHETTI D,LACCABUE D,et al.Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3,JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting［J］.Biochem Pharmacol,2009,78(9):1139-1147.
［5］TAI YT,LANDESMAN Y,ACHARYA C,et al.CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma:molecular mechanisms and therapeutic implications［J］.Leukemia,2014,28(1):155-165.
［6］GUADAGNOLI M,KIMBERLEY FC,PHAN U,et al.Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas［J］.Blood,2011,117(25):6856-6865.
［7］DETAPPE A,REIDY M,YU Y,et al.Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma［J］.Nanoscale,2019,11(43):20485-20496.
［8］DIAMANTIS N,BANERJI U.Antibody-drug conjugates-an emerging class of cancer treatment［J］.British Journal of Cancer,2016,114(4):362-367.
［9］FU Z,LI S,HAN S,et al.Antibody drug conjugate:the"biological missile" for targeted cancer therapy［J］.Signal Transduct Target Ther,2022,7(1):93.
［10］TRUDEL S,LENDVAI N,POPAT R,et al.Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159):a dose escalation and expansion phase 1 trial［J］.Lancet Oncol,2018,19(12):1641-1653.
［11］TAI YT,MAYES PA,ACHARYA C,et al.Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma［J］.Blood,2014,123(20):3128-3138.
［12］WEI J,YANG Y,WANG G,et al.Current landscape and future directions of bispecific antibodies in cancer immunotherapy［J］.Front Immunol,2022,13:1035276.
［13］MOREAU P,GARFALL AL,VAN DE DONK N,et al.Teclistamab in relapsed or refractory multiple myeloma［J］.N Engl J Med,2022,387(6):495-505.
［14］LESOKHIN AM,TOMASSON MH,ARNULF B,et al.Elranatamab in relapsed or refractory multiple myeloma:phase 2 MagnetisMM-3 trial results［J］.Nat Med,2023,29(9):2259-2267.
［15］JAGANNATH S,RICHTER J,DHODAPKAR MV,et al.Patterns of response to 200 mg Linvoseltamab in patients with relapsed/refractory multiple myeloma:Longer follow-up of the linker-MM1 study［J］.Blood,2023,142(Supplement 1):4746.
［16］BAR N,MATEOS MV,RIBAS P,et al.Alnuctamab (ALNUC;BMS-986349;CC-93269),a2+1 B-cell maturation antigen (BCMA)×CD3 T-cell engager (TCE),administered subcutaneously (SC) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM):updated results from a phase 1 first-in-human clinical study［J］.Blood,2023,142:2011.
［17］SPINNATO P,BAZZOCCHI A,BRIOLI A,et al.Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma:a comparison of results in different phases of the disease［J］.European Journal of Radiology,2012,81(12):4013-4018.
［18］DE NOVELLIS D,FONTANA R,GIUDICE V,et al.Innovative anti-CD38 and anti-BCMA targeted therapies in multiple myeloma:Mechanisms of action and resistance［J］.Int J Mol Sci,2022,24(1)：645.
［19］RODRIGUEZ-OTERO P,AILAWADHI S,ARNULF B,et al.Ide-cel or standard regimens in relapsed and refractory multiple myeloma［J］.N Engl J Med,2023,388(11):1002-1014.
［20］MARTIN TG,MADDURI D,PACAUD L,et al.Cilta-cel,a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma ［J］.Future Oncol,2023,19(34):2297-2311.
［21］SAN-MIGUEL J,DHAKAL B,YONG K,et al.Cilta-cel or standard care in lenalidomide-refractory multiple myeloma［J］.N Engl J Med,2023,389(4):335-347.
［22］JIANG H,DONG B,GAO L,et al.Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma［J］.J Clin Oncol,2021,39(15_suppl):8014.
［23］SPERLING AS,DERMAN BA,NIKIFOROW S,et al.Updated phase I study results of PHE885,a T-Charge manufactured BCMA-directed CAR-T cell therapy,for patients (pts) with r/r multiple myeloma (RRMM)［J］.J Clin Oncol,2023,41(16_suppl):8004.
［24］COSTELLO CL,COHEN AD,PATEL KK,et al.Phase 1/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies［J］.Blood,2020,136(Supplement 1):29-30.
［25］SHAH N,CHARI A,SCOTT E,et al.B-cell maturation antigen (BCMA) in multiple myeloma:rationale for targeting and current therapeutic approaches［J］.Leukemia,2020,34(4):985-1005.
［26］GUO R,LU W,ZHANG Y,et al.Targeting BCMA to treat multiple myeloma:Updates from the 2021 ASH annual meeting［J］.Front Immunol,2022,13:839097.
［27］MA J,ZHANG S,YANG N,et al.Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen:Applications in PET imaging of multiple myeloma ［J/OL］.Eur J Nucl Med Mol Imaging,2024［2024-09-11］.https://link.springer.com/article/10.1007/s00259-024-06907-3.DOI:10.1007/s00259-024-06907-3.
［28］WEI W,ZHANG Y,ZHANG D,et al.Annotating BCMA expression in multiple myelomas ［J］.Mol Pharm,2022,19(10):3492-3501.
［29］SONG L,JIANG S,YANG Q,et al.Development of a novel peptide-based PET tracer ［(68)Ga］Ga-DOTA-BP1 for BCMA detection in multiple myeloma［J］.J Med Chem,2024,67(17):15118-15130.
［30］THOMAS E,MATHIEU C,MORENO-GAONA P,et al.Anti-BCMA immuno-NanoPET radiotracers for improved detection of multiple myeloma［J］.Advanced Health Care Materials,2022,11(2):e2101565.